biotech
Sichuan Kelun-Biotech Biopharmaceutical
Sichuan Kelun-Biotech Biopharmaceutical Co.,
Sichuan Kelun-Biotech Biopharmaceutical is a biotech organization headquartered in CN. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTr
Company details
- Status
- Public
- HQ
- CN
- Programs
- 0
- Drugs
- 0
- Patents
- 0
Quick answer
Sichuan Kelun-Biotech Biopharmaceutical is a biotech organization headquartered in CN. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.
Company snapshot
Sichuan Kelun-Biotech Biopharmaceutical is a biotech organization headquartered in CN. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.
- Profile assembled from SEC, FDA, ClinicalTrials.gov, and USPTO public sources.
Public regulatory, clinical, patent, and corporate records for Sichuan Kelun-Biotech Biopharmaceutical. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Merck’s Billion-Dollar Bet on TROP2: Regulatory Updates and Implications
- approval
Kelun and Merck's Lung Cancer Combo Shows Promise in China
- deal
Merck-Kelun ADC's Strategic Wins and Takeda's Antitrust Loss
- approval
Merck's TroFuse-005 Trial Results: Implications for Investors and Pharma Teams
- approval
Kelun-Biotech Secures New Drug Approval for SKB118: Investor and BD Guide
Recent coverage
Kelun-Biotech Secures New Drug Approval for SKB118: Investor and BD Guide
Kelun-Biotech has secured Investigational New Drug (IND) approval from China's CDE for its novel PD-1 x VEGF bispecific antibody, SKB118. This milestone opens the door for clinical development and presents significant opportunities and competitive considerations for the pharmaceutical industry.
Merck's TroFuse-005 Trial Results: Implications for Investors and Pharma Teams
Merck's TroFuse-005 trial evaluating Sacituzumab Tirumotecan has met primary endpoints of overall survival and progression-free survival in advanced endometrial cancer. This article explores the implications for investors and pharmaceutical teams.
Merck-Kelun ADC's Strategic Wins and Takeda's Antitrust Loss
This article delves into Merck-Kelun ADC's recent achievements in China and the implications of Takeda's significant antitrust loss, providing strategic insights for business development teams and investors.
Merck-Kelun Lung Cancer Drug Cuts Tumor Progression Risk by 65%
Merck-Kelun's recent trial results indicate a significant breakthrough in lung cancer treatment, with a 65% reduction in tumor progression risk. This article explores the implications for the pharmaceutical industry.
Congress & presentations
- PresentationPhase I data of silevertinib in EGFR-mutant non-small cell lung cancer
- CongressASCO 2026
Momentum signals
Momentum
Proprietary activity score for Sichuan Kelun-Biotech Biopharmaceutical.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitive landscape
Recent activity
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Sichuan Kelun-Biotech Biopharmaceutical?
-
Is Sichuan Kelun-Biotech Biopharmaceutical publicly traded?
-
What drugs does Sichuan Kelun-Biotech Biopharmaceutical develop or market?
-
What are the latest developments for Sichuan Kelun-Biotech Biopharmaceutical?
-
What therapeutic areas does Sichuan Kelun-Biotech Biopharmaceutical focus on?